Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 1

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 1
---
 from Sorrento pursuant to the Sorrento SPA (as defined and described elsewhere in this prospectus) to be transferred to Oramed (the “Transferred Warrants”).
See the section titled “Certain Relationships and Related Party Transactions” for additional information regarding the Scilex-Oramed SPA and transactions related thereto.

We are registering the resale of the Resale Shares as required by that certain Registration Rights Agreement between us and Oramed, dated
September 21, 2023 (the “Oramed RRA”).

Our registration of the Resale Shares covered by this prospectus does not mean that the
Selling Stockholder will offer or sell any of the Resale Shares. The Selling Stockholder may sell the Resale Shares covered by this prospectus in a number of different ways and at varying prices. For additional information on the possible methods of
sale that may be used by the Selling Stockholder, you should refer to the section of this prospectus titled “Plan of Distribution” beginning on page 259 of this prospectus.

We will not receive any of the proceeds from the resale of the Resale Shares sold by the Selling Stockholder. We will, however, receive
proceeds of up to $65,000 from the exercise of the remaining Penny Warrants, assuming the exercise in full of all of the Penny Warrants for cash, but not from the sale of the shares of Common Stock issuable upon such exercise.

The sale of all the Resale Shares being offered in this prospectus could result in a significant decline in the public trading price of our
securities. Despite such decline in the public trading price, the Selling Stockholder may still experience a positive rate of return on the securities they acquired due to the difference in the purchase prices. Based on the closing price of our
Common Stock of $5.43 on May 5, 2025, Oramed may experience a potential profit of up to $5.42 per Resale Share given that the exercise price of the Penny Warrants is $0.01 per share.

No underwriter or other person has been engaged to facilitate the sale of the shares of our Common Stock in these offerings. The Selling
Stockholder may be deemed to be an “underwriter” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), of the Resale Shares that it is offering pursuant to this prospectus. We will bear all costs,
expenses and fees in connection with